Insilico Medicine Inc. has synthesized fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer.

Insilico Medicine Inc. has synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of obesity, autoimmune disease and inflammatory disorders.

Insilico Medicine Inc. has synthesized cyclin-dependent kinase 8/19 (CDK8/19) dual inhibitors reported to be useful for the treatment of autoimmune disease and cancer.

Insilico Medicine Inc. has synthesized 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Insilico Medicine Inc. has prepared and tested new spirocyclic mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer and viral infections.

Insilico Medicine Inc. has identified compounds acting as tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer and metabolic disease.

Insilico Medicine Inc. has divulged compounds acting as kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Insilico Medicine Inc. has disclosed E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.

Insilico Medicine Inc. has identified new salt-inducible kinase inhibitors potentially useful for the treatment of cancer.

Insilico Medicine Inc. has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of autoimmune and inflammatory disorders.